Introduction
Bladder cancer is the ®fth most common cancer in the Western world, aecting 4% of cancer patients, and is the cause of 2% of all cancer related deaths. It is estimated that in 1997, approximately 54 500 Americans will be newly diagnosed with bladder cancer, and 11 700 will die of this disease (Parker et al., 1997) . In spite of numerous research eorts, little is known about the molecular basis of bladder cancer. Cytogenetic studies of primary bladder cancer have identi®ed recurrent karyotypic aberrations, including i(5p), +7, 79, and del(11p), as well as deletions on chromosome 10q (Gibas et al., 1984; Berger et al., 1986; Babu et al., 1987; Smeets et al., 1987; Vanni et al., 1988) . Others reported structural abnormalities involving chromosomes 1, 3, 8 and 17 (Sandberg, 1990) . Frequent allele losses were detected on chromosome arms 4p, 8p, 9p, 9q, 11p and 17p (Knowles et al., 1994) . A study using comparative genomic hybridization (CGH) identi®ed losses aecting primarily chromosomes 3p, 8p, 9, 10q, 11, 12q, and 17p in over 20% of the 26 bladder tumors examined (Kallioniemi et al., 1995) .
The suggestion that chromosome 10 might be involved in bladder cancer emerged from a study conducted by Wang et al. (1994) using¯uorescent in situ hybridization (FISH) to interphase nuclei. Losses of chromosome 10 were detected in two (28%) of seven primary bladder cancers. A report using CGH, identi®ed losses on chromosome 10 in seven (27%) of the 26 primary bladder tumors examined (Kallioniemi et al., 1995) . Lastly, a genome-wide loss of heterozygosity (LOH) study identi®ed low frequencies of allelic losses on chromosome 10p, in three (5%) of 60 cases and on chromosome 10q in ®ve (8.5%) of 59 cases (Knowles et al., 1994) .
Following these leads, we have directed our research toward identifying chromosome 10 regions that might be involved in high grade bladder cancer but were not identi®ed and or pin pointed in the lower grades, in previous studies (Knowles et al., 1994; Kallioniemi et al., 1995) . Frequent loss of alleles at a speci®c chromosomal region in cancer tissue is highly associated with inactivation of a tumor suppressor gene (Levine and Franks, 1992) .
Results
The search for allele losses on chromosome 10 was carried out in two successive rounds using a total of 19 microsatellite polymorphic sequences (Figure 1 ). For most of the markers, the observed heterozygosity was 60 ± 90%, frequently lower than the reported heterozygosity (Collins et al., 1996 and the Genetic location database, LDB, University of Southampton, UK). D10S216 showed very low (45%) heterozygosity.
In the ®rst round of the search for LOH, we analysed 20 grade III invasive transitional cell carcinomas in seven polymorphic microsatellite loci (D10S189, D10S211, D10S219, D10S215, D10S583, D10S190, D10S212). The ®rst round was conducted to establish the broad locations of common chromosomal regions with allele losses. The second round included an additional 12 microsatellite markers, providing high-density coverage (one microsatellite per 10 cM region or less) of the long arm of chromosome 10 (10q) (Figure 1) . Figure 2 illustrates LOH in several bladder cancer specimens in dierent microsatellite loci. Overall, nine (45%) of 20 informative specimens had allelic losses on chromosome 10q. The short arm of chromosome 10 was not aected (Figures 1 and 3) .
The most frequent LOH was detected at the D10S215 locus. Four (29%) of the 14 informative specimens had an allele loss within that locus (Figures 1 and 3) . The minimal region with allele losses around D10S215 was restricted to a region of 2.52 cM between the centromeric marker D10S1644 and the telomeric marker D10S541 (Figure 3 ) (distances according to Collins et al., 1996 and the LDB database). Another region with LOH was detected at D10S587 locus where two (11%) of 18 informative specimens showed allele losses (Figures 1 and 3) .
There was no signi®cant statistical correlation between LOH and the pathological classi®cation, race, age, family history or the outcome of the disease among our patients.
Discussion
Frequent allelic losses at speci®c chromosomal regions are frequently associated with inactivation of tumor suppressor genes (Levine and Franks, 1992) . Frequent LOH on chromosome 10 has been reported in a variety of cancers, including glioma, glioblastoma multiforme, prostate cancer, endometrial cancer, chondrosarcoma, bladder cancer, malignant melanoma, and follicular thyroid tumors (Knowles et al., 1994; Gray et al., 1995; Fults and Pedone, 1993; Ittmann, 1996; Trybus et al., 1996; Lacombe et al., 1996; Rasheed et al., 1995; Raskind et al., 1996; Nagase et al., 1996; Zedenius et al., 1996; Isshiki et al., 1993) . A limited number of studies have indicated the potential involvement of chromosome 10 in bladder cancer (Knowles et al., 1994; Kallioniemi et al., 1995; Wang et al., 1994) . These studies included detection of deleted regions by FISH to interphase nuclei, a CGH study, and a limited analysis of allele losses on chromosome 10 in transitional cell carcinomas. However, the reported frequency of allele losses on chromosome 10 in bladder transitional cell carcinomas was low (5 ± 8%) (Knowles et al., 1994) .
We thought that genetic alterations on chromosome 10 might be associated with more advanced, high grade bladder cancer. The present study is the ®rst study that has applied a large battery of chromosome 10 microsatellite probes to screen advanced, high-grade (grade III invasive), transitional cell carcinomas. Initially, we have sought to identify a region or regions with frequent allele losses and then to narrow down each region as a site for a candidate tumor suppressor gene. We found a cluster of allele losses around the D10S215 locus, the minimal region with LOH was restricted to 2.52 cM region between markers D10S1644 and D10S541 at 10q22.3-10q23.1. This tight cluster of allele losses in a relatively small region strongly suggests that this region harbors a candidate tumor suppressor gene or genes, which was inactivated in 29% of the informative advanced bladder cancer specimens tested. The same region has been shown to have high frequency of LOH in several other cancers as well (Figure 4) (Knowles et al., 1995; Gray et al., 1995; Ittmann, 1996; Trybus et al., 1996; Albarosa et al., 1996; Rasheed et al., 1995; Steck et al., 1997) .
Among the genes mapped within the 2.5 cM minimal region that we identi®ed is the newly cloned
Figure 2 Examples of allelic losses in PCR-ampli®ed microsatellite loci D10S1717, D10S1644, D10S587, D10S215, and D10S541 in advanced bladder cancers. The specimen numbers are shown at the top of each pair of lanes. T and N, matched DNA samples isolated from tumor and normal tissue, respectively. The radioactive PCR products were resolved using 6% denaturing polyacrylamide gel electrophoresis Figure 3 A cluster of chromosome 10 allele losses in advanced bladder cancers. Only specimens with allele losses are presented. Open circles, informative samples; barred circles, noninformative samples; ®lled-in circles, LOH. A boxed region within a column indicates the maximal extent of the region with LOH in that tumor. The bar on the right side of the ®gure represents the smallest common region with LOH at 10q22.3-q23.1. This region may harbor a bladder cancer tumor suppressor gene. The minimal region, 2.52 cM, is located between markers D10S1644 and D10S541 (distances according to Collins et al., 1996) gene MMAC1/PTEN, a candidate tumor suppressor gene in advanced cancers (Steck et al., 1997; Li et al., 1997) . MMAC1/PTEN is a phosphatase that is homozygously deleted or mutated in some glioma, breast cancer and prostate cancer cell lines and specimens. Most of the alterations in this gene have been detected in advanced cancers (Steck et al., 1997; Li et al., 1997) . It has long been postulated that protein tyrosine phosphatases may act as tumor suppressors because of their ability to counteract the oncogenic activity of some protein tyrosine kinases. As the minimal region suspected to harbor a tumor suppressor gene in our study is a large region (2.5 cM) that may contain several genes, it remains to be tested whether MMAC1/PTEN is also inactivated in some of the advanced bladder cancers.
Another region with less frequent allele losses (11%) in our study, around the D10S587 locus at 10q26.1 (Figure 1) , was also aected in prostate cancers and gliomas and in a CGH study of bladder cancer ( Figure  4) (Kallioniemi et al., 1995; Albarosa et al., 1996; Rasheed et al., 1995) . The minimal region with a reduced gene copy number in the bladder cancer CGH study was localized to 10q25-qter, a very large region that includes the 10q26.1 region as well (Kallioniemi et al., 1995) . Our results, also tested in a limited number of advanced bladder cancers, do not provide strong support for the assumption that chromosome 10q25-qter harbors a bladder cancer tumor suppressor gene.
The high frequency of allele losses and their cluster within 2.5 cM region at 10q22.3 ± 10q23.1 in the present study suggests that inactivation of a tumor suppressor gene within that region is a common event, aecting *1/3 of the high-grade invasive bladder cancers.
Materials and methods

Tissue samples
All bladder cancer specimens were obtained through the department of pathology at the University of Texas MD Anderson Cancer Center. Bladder cancer patients were pathologically staged according to the American Joint Committee on Staging (Beahrs et al., editors, 1992) . Of the 20 patients all were male, with mean age of 65 years (range 54 ± 79). All patients except one had radical cystoprostatectomies for urothelial carcinoma. One patient had a partial cystectomy. All had muscle invasive disease, however 10 patients had only super®cial muscular propria invasion (T3a). The other 10 patients had deep muscle Figure 4 A summary of selected studies of chromosome 10 allele losses in prostate cancer, glioma and bladder cancer. The extent of allele losses in each study is indicated by vertical bars. The smallest common region with LOH in advanced bladder cancer (this study), around the D10S215 locus, is boxed. Distances are according to Collins et al. (1996) invasion through to the perivesicular fat (T3b). Local lymph node metastases were present in nine of 10 patients with stage T3b, while only two patients with stage T3a had lymph node metastases. Distant metastases occurred in six.
Of the 19 patients for whom cystoprostatectomy were performed, adenocarcinoma of the prostate was demonstrated in seven patients and PIN in four patients. The growth pattern of the bladder tumor was recorded as papillary transitional cell carcinoma (TCC) in six of 20 patients and non-papillary or¯at TCC in 14 of 20 patients.
Additional histologic subtypes most commonly included TCC with grandular and squamous dierentiation, (7 patients). All patients had transitional cell carcinoma grade III, except one patient with grade II TCC. One case showed a sarcomatoid component while in one patient, a predominant neuroendocrine carcinoma component was noted. Concurrent carcinoma-in-situ was present in ®ve patients in conjunction with both¯at and papillary lesions.
History In three patients noninvasive papillary TCC had manifested up to 9 years before the onset of the invasive non papillary component.
Outcome Seven patients are dead. Eight patients were in apparent remission however one patient died of disseminated gastric carcinoma, 2 years post radical cystoprostatectomy. Five patients were lost to follow up of whom two were reported 1 year post-radical surgery to be alive and stable with disease. Time to death in seven patients from the time of radical cystoprostatectomy varied from 2 months to 24 months with median survival of 8 months.
Specimens for DNA extraction Four fresh and 16 formalin-®xed paran-embedded samples were used. Control samples were obtained from normal bladder tissue, adipose tissue, or uninvolved lymph nodes from the same cystectomy specimen.
DNA extraction, PCR ampli®cation and LOH in microsatellite sequences
Normal tissue surrounding a bladder cancer lesion was microdissected and removed from paran-embedded samples. The remaining cancerous specimen was deparanized in xylene, washed with 100% ethanol and 95% ethanol, and rehydrated overnight in lysis buer (50 mM Tris-HCl, pH 7.5; 50 mM EDTA; 150 mM NaCl; 1% SDS). All samples were then scraped across a wire mesh in a petri dish with 5 ml of lysis buer until a homogeneous consistency was obtained. The material was then transferred into a 15 ml tube, proteinase K was added (1 mg/ ml), and the samples were incubated overnight at 428C with slow agitation. Samples with any undigested proteins were re-spiked with an additional aliquot of proteinase K and digested to completion. DNA recovery and PCR ampli®cation of microsatellite sequences were carried out as previously described (Kagan et al., 1995) . The signi®cance of LOH in microsatellite sequences was correlated with gender, race, family history, and age, essentially as previously described (Kagan et al., 1995) .
Microsatellite sequences and maps
Microsatellite sequences and the heterozygosity of each marker were obtained from the genome database at www.gdb.org/. Chromosomal maps and distances were obtained from the LDB at ftp://cedar.genetics.soton.ac.uk/ pub/chrom10/map (Collins et al., 1996) .
Abbreviations LOH, loss of heterozygosity; FISH,¯uorescence in situ hybridization; CGH, comparative genomic hybridization; PCR, polymerase chain reaction; MMAC, the mutated gene in multiple advanced cancers; PTEN, phosphatase and tensin homolog gene
